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A Case of Pyoderma Gangrenosum
Christopher T. Miller, MD
Case Report
A 60-year-old man with past medical history of hypertension, 
post-traumatic stress disorder, major depression, hepatic 
steatosis, chronic kidney disease, and untreated hepatitis C virus 
(genotype 1b) initially presented to the outpatient primary care 
clinic with a chief complaint of an extremely painful right lower 
extremity ulcer that had developed and grown progressively 
larger after mild trauma against a metal corner 4 months prior 
to the appointment. He admitted to picking at the granulation 
tissue that would develop over the ulcer. He was treating the 
ulcer with antibiotic ointment. On initial exam, the ulcer was 
about 2x2 cm, located a few inches above the ankle on the lateral 
right leg, and associated with some lower extremity edema. His 
primary care physician was concerned at the time for a venous 
stasis ulcer. Initial plain films of the leg were obtained, and these 
did not show any evidence of osteomyelitis. A lower extremity 
doppler ultrasound did not reveal a deep vein thrombosis that 
could account for the edema. He had no signs of heart failure, 
ascites, or volume overload otherwise. He was referred to 
podiatry and wound care.
The patient was assessed by podiatry about 2 weeks later. The 
podiatrist noted mycotic toenail infection on both feet, mild 1+ 
edema, and noted that the lesion had a small eschar. He also felt 
the wound was a venous stasis ulcer and recommended daily 
collagenase covering for enzymatic wound debridement.
The patient was subsequently seen over the next few weeks at 
wound care clinic. There, the ulcer was noted to have a bit of 
sloughing material which was removed with scissors each time. 
The wound did not clinically appear infected at any of these 
appointments. The patient noted worsening pain with each 
mechanical debridement.
The patient was seen by surgery who also initially felt the 
patient had a vascular ulcer. Compression wrappings and 
Dermagraft were employed as treatment. The patient had an 
ankle-brachial index calculated with ultrasound. The results 
of this study were normal. An arteriogram of the extremity 
was roughly normal. Surgery noted that with each mechanical 
debridement, that patient returned to clinic in more pain with 
more necrotic material, and the ulcer increased in size and 
depth with each appointment.
The possibility of pyoderma gangrenosum was eventually 
considered by surgery. A biopsy of the ulcer was performed, 
and the patient was referred to rheumatology about 7 months 
after initial presentation. His wound appeared significantly 
more edematous and inflamed after the biopsy. A tendon 
was found to be exposed at the wound base in rheumatology 
clinic. The patient was tested for vasculitis, but was negative 
for cryoglobulins, rheumatoid factor, and anti-neutrophil 
cytoplasmic antibodies (ANCAs). Biopsy results were consistent 
with pyoderma gangrenosum. He was started on prednisone, 
but the wound became foul-smelling. The patient was directly 
admitted to the inpatient medicine floors after a rheumatology 
follow-up exam and was started on antibiotics. He was seen as an 
inpatient by an infectious disease specialist and was diagnosed 
with cellulitis.
The patient was successfully treated for the cellulitis with a course 
of antibiotics. Dermatology was consulted and felt the biopsy 
results in addition to history of wound pathergy (worsening 
lesion with mechanical manipulation or mild trauma) was 
consistent with a diagnosis of pyoderma gangrenosum. 
The overall concern of the medical team was that his exposed 
tendon would become infected and track infection to other 
areas of the leg. The team felt the tendon should be excised, 
but there was concern further debridement could lead to 
further wound pathergy. The consensus was that he should be 
sufficiently immune-suppressed before surgical therapy, then 
have the tendon removed before attempting possible skin graft.
The patient was continued on steroids. He was also considered 
for concurrent cyclosporine; however, he was deemed to not 
be a candidate secondary to decreased renal function. He 
was considered for infliximab as a second-line treatment. 
Incidentally, the patient had had close contact with a relative 
with active tuberculosis (TB) within the past 5 years, so there 
was concern that infliximab could precipitate reactivation 
of latent tuberculosis. Although he had a negative purified 
protein derivative (PPD) test, the patient was on cortico-
steroids, and the infectious disease team felt the likelihood of a 
false-negative in this setting was high. He was therefore started 
on empiric isoniazid for latent TB infection and was to begin 
infliximab 1 month into this treatment. He was to follow up 
with rheumatology and surgery. To date, his wound appears to 
be accumulating granulation tissue indicating recovery after a 
single infusion of infliximab.
Discussion
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis 
that causes skin papules or vesicles that eventually progress to 
ulcerations. Lesions are usually located on the lower extremities 
and are often multiple in number. Ulcerations are painful (pain is 
usually out of proportion to exam) and generally have a purulent 
base with rough, violaceous border. Tendons and muscles can 
become exposed in the wound. Wounds can demonstrate 
pathergy, or wound exacerbation with mechanical manipulation. 
The pathophysiology of PG is incompletely understood. A 
better understanding may come with further study of the 
inflammasome. Inflammasomes are intracellular macromol-
ecules that sense foreign or pathologic material and cause 
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cellular release of “warning” mediators. Their study has led to 
a better understanding of a multitude of familial autoimmune 
diseases. One particular mutation to the proline-serine-
threonine phosphatase interacting protein1 (PSTPIP1) gene 
has been associated with PAPA (pyogenic arthritis with 
pyoderma gangrenosum and acne syndrome). Mutations in 
PSTPIP1 are believed to cause increased interaction with the 
molecule pyrin. The exact signaling cascade of this interaction 
is not yet certain, however, the consequence appears to be 
increased release of the inflammatory mediator IL-1β. Targeted 
therapies against IL-1β, however, have only been reported in 
limited anecdotal accounts, so the PSTPIP1 mutation may 
cause additional consequences that are not yet known.
PG is associated with systemic disease in 50% or more of 
cases. (Debade et al 2011) Examples include inflammatory 
bowel disease (IBD), rheumatoid arthritis (RA), and acute 
myeloblastic leukemia (AML) or lymphoproliferative disease 
(PG can sometimes be a paraneoplastic disorder in these cases). 
It can also occur in idiopathic cases.
PG can be classified into 4 different subtypes based on clinical 
presentation and histopathology: ulcerative, pustular, bullous, 
and vegetative. Patients typically present with one subtype of PG. 
Ulcerative PG is characterized clinically by ulcers with eroded 
borders and surrounding inflammation and histologically 
by centrally neutrophilic abscess and marginal lymphocytic 
angiocentric infiltrates. This disease subtype generally presents 
with progression of small papules into the aforementioned 
ulcerations, which can be fatal in its most severe form.
Pustular PG has clinical findings of inflammatory pustules 
(measuring less than 8mm) and dense neutrophilic infiltrates 
in perifollicular, follicular, and dermal zones on histology. It is 
often associated with IBD flares. This disease subtype generally 
manifests similarly to the ulcerative subtype, but does not 
progress to such a severe extent.
Bullous PG has a clinical presentation of superficial painful, 
sometimes inflamed bullae that can progress to ulcers. 
Histologically it appears as a subepidermal bulla with intraepi-
dermal and dermal neutrophils. It often heralds a poor prognosis 
if associated with hematologic malignancy.
Vegetative PG is characterized by a painless single shallow 
ulcer with slow progression. It shows pseudoepitheliomatous 
hyperplasia, dermal neutrophilic abscess, sinus tracts, and 
palisading granulomas on histology. It is usually associated with 
idiopathic cases. It is generally nonaggressive.
Differential diagnoses for PG include vascular insufficiency, 
atypical mycobacterium, fungal infection, spider or insect 
bite, vasculitis, gummatous syphilis, gangrene, drug reaction, 
malignancy, antiphospholipid syndrome, amebiasis, halogeno-
dermas (superficial reaction to halogen compounds), factitial 
disorder, and viral infection (like Herpes simplex virus). 
Diagnosis is established by history and biopsy consistent with 
PG, and exclusion of other disorders.
Treatment for PG is generally based on case reports and expert 
opinion, as so few cases have been diagnosed and documented 
that only one double-blinded, randomized study exists to date. 
For the purposes of this case report, a treatment algorithm 
suggested in early 2011 in Dermatologic Therapy has been 
referenced as one of the most up-to-date references. The 
algorithm consists of both local and systemic therapy. Local 
therapy alone may be considered in mild cases. Local treatments 
include topical immunosuppressants such as corticosteroids 
(clobetasol) or tacrolimus. Numerous dressing types can 
be applied with a goal of a moist, but not overtly wet or dry 
lesion. Mechanical or chemical debridement is contraindicated 
due to pathergy. Systemic treatment, generally with cortico-
steroids, is first line therapy in most cases of PG. Although 
experts generally consider steroids the first line therapy, no 
randomized, double-blind trials exist to support their use. 
Prednisone is commonly used and is historically initiated at 
1-2mg/kg. During initiation of therapy, underlying systemic 
disease like IBD or RA should be treated as well if uncontrolled. 
This can often lead to improvement in PG, although treatment 
specifically targeted at PG should continue, as flares of PG and 
systemic disease may occur independently despite coexistence 
in a single patient. After treatment initiation, improvement 
of wound pain, decrease in the violaceous appearance of the 
wound, and flattening of wound borders indicates healing. No 
new lesions should appear if the disease process is adequately 
controlled. At this point, steroid tapering should be considered. 
A steroid-sparing agent may be added if there is any recurrence.
In refractory cases of PG, diagnostic steps should be reviewed 
or even repeated to determine if the diagnosis of PG is correct. 
If diagnosis is felt to be certain, steroids should be pulsed or a 
second-line therapy added. The aforementioned assessment of 
healing and disease control remains a guidepost to determine 
when immunosuppressants can be tapered. Second-line 
treatments are numerous. Cyclosporine is one of the most 
widely used agents, as it is historically backed by some of the 
most literature amongst treatments. Infliximab, an anti-TNF 
immunomodulator, is the only PG treatment to date that 
has been examined in a randomized, double-blinded study.1 
Published in 2006 by Brooklyn et al, this 30-patient study 
compared infliximab to placebo and was found to be superior, 
even in patients without known underlying concurrent disease 
(although this study did not compare infliximab head-to-head 
with first line therapy like steroids or cyclosporine). Other 
second-line systemic treatments that have been described 
include methotrexate, azathioprine, cyclophosphamide, 
mycophenolate mofetil, tacrolimus, dapsone, chlorambucil, 
IVIG, colchicine, interferon alpha, etanercept, adalimumab, 
and alefacept. The use and efficacy of these therapies is largely 
anecdotal. Hyperbaric oxygen, skin grafting, and plasma-
pheresis are amongst additional tertiary therapies that have 
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been described and may be considered as concurrent therapy to 
the algorithm suggested above. Consensus expert opinion has 
generally advised against surgical intervention, however, when 
necessary, it should be postponed until sufficient immunosup-
pression and disease control has been established.
Conclusion
PG is a rare, painful, ulcerating skin disorder that often affects 
the lower extremities. The lesions can demonstrate pathergy and 
may be associated with an underlying systemic disease such as 
IBD, RA, or various hematologic disorders. Diagnosis is based 
on clinical history, biopsy, and exclusion. Treatment consists of 
local topical immunosuppressants and wound care, avoidance 
of debridement, and usually systemic corticosteroids. Treatment 
failure or relapse is treated with a second-line agent such as 
cyclosporine or infliximab, usually in conjunction with cortico-
steroids. Infliximab is the only therapy that has demonstrated 
efficacy in a randomized, double-blinded, placebo-controlled 
trial, although significant literature exists to support the use of 
corticosteroids, cyclosporine, and many other agents. Surgical 
intervention should only be considered if adequate therapy has 
been established by symptoms and signs of decreasing pain, 
decreased wound discoloration, wound margin flattening, and 
lack of appearance of new lesions.
Our patient in this case had a history and biopsy consistent 
with PG. His wound demonstrated pathergy and continued to 
worsen as aggressive mechanical debridement was pursued 
under the assumed diagnosis of venous insufficiency. When 
the diagnosis was established, he did not initially respond to 
steroids. Investigation for other systemic diseases was unfruitful. 
He was deemed to not be a candidate for cyclosporine due to 
compromised renal function, so infliximab was added instead. 
He appears to be responding to this combined treatment regimen.
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